Abstract
IN BRIEF Type 2 diabetes and its associated comorbidities often require polypharmacotherapy, which may result in poor adherence to treatment. This study evaluated, using subjective patient and physician questionnaire surveys, the impact of pill burden and its associated consequences on patients treated with vildagliptin as add-on to metformin, a fixed-dose combination of vildagliptin/metformin, or another dual oral antidiabetic therapy. Patients’ responses were also analyzed by age (<65 or ≥65 years). The surveys revealed that a high pill count in antidiabetic therapy constitutes a large burden for patients with type 2 diabetes. Treating physicians are aware of the problems that result from a high pill burden, and a majority of them prefer prescribing fixed-dose combinations that have better efficacy and tolerability to reduce pill burden.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
